GlassScriptPhysician profile
Margaret Cooper
NPI 1750305702
$3,258.16
in general payments reported to CMS, 2019-2025
22 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Adult Health (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $186).
See the full distribution for Adult Health (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $658 · 2022: $632 · 2023: $836 · 2024: $660 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,968.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $753.04 | 2021-2024 | |
| Pfizer INC. | $688.76 | 2021-2025 | |
| Abbott Laboratories | $428.23 | 2021-2025 | Aveir, Navitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.28 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $194.71 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $158.66 | 2021-2025 | Wainua |
| Janssen Pharmaceuticals, INC | $122.42 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.12 | 2021-2024 | Verquvo |
| Amgen INC. | $81.78 | 2021-2024 | Repatha |
| Lexicon Pharmaceuticals, INC. | $68.41 | 2023-2024 | Inpefa |
| Cvrx, INC. | $67.67 | 2022-2025 | Barostim Neo System |
| E.R. Squibb & Sons, L.L.C. | $64.60 | 2021-2024 | Camzyos |
| Inspire Medical Systems, INC. | $62.46 | 2023-2024 | Inspire |
| Boston Scientific Corporation | $58.15 | 2025 | Cds - Mct/Cem Monitoring |
| Scpharmaceuticals INC. | $49.57 | 2023-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.80 | 2024 | Injectafer |
| Sanofi-Aventis U.S. LLC | $36.50 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $27.80 | 2022-2023 | Onpattro |
| Angiodynamics, INC. | $27.28 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.80 | 2022 | |
| Atricure, INC. | $13.65 | 2022 | |
| Esperion Therapeutics, INC. | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.